⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Cross-Species Geroprotector Screening
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-01 — Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions.: cross-connection with senolytics: [animal-model] The tree shrew study connects senolytic evaluation with cross-species geroprotector screening by comparing aging signatures and dasatinib+quercetin responses with human patterns; reported concordance does not establish predictive validity for human clinical outcomes. (novelty: 4)
- 2026-09-29 — Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies: cross-connection with ampk-activators: Yeast/worm/fly concordance for AMPK activation is an example of the cross-species screening logic used to prioritize geroprotector candidates. (novelty: 3)
- 2026-08-31 — A cross-species drug-discovery platform to accelerate the identification of lifespan-extending interventions.: Integrated high-throughput screening platform spanning yeast, C. elegans, Drosophila, killifish, and mice tested 400+ compounds and prioritized multi-species geroprotector hits converging on conserved longevity pathways; abstract does not disclose specific named hits or human data (animal-model). [animal-model] (novelty: 4)
Open questions
Related
Contributing findings
A cross-species drug-discovery platform to accelerate the identification of lifespan-extending interventions.
31-aug-2026
novelty 4
per-area 4
strengthens